Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Alliance for Clinical Trials in Oncology
Actuate Therapeutics Inc.
Verastem, Inc.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Hoffmann-La Roche
Pfizer
M.D. Anderson Cancer Center
Providence Health & Services
Servier
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
Trishula Therapeutics, Inc.
SWOG Cancer Research Network
Fox Chase Cancer Center
EpicentRx, Inc.
Sun Yat-sen University
BeiGene
SWOG Cancer Research Network
Galvanize Therapeutics, Inc.
Coherus Oncology, Inc.
Beijing Chest Hospital, Capital Medical University
Spanish Lung Cancer Group
Canadian Cancer Trials Group
Wake Forest University Health Sciences
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
AIO-Studien-gGmbH
Intergroupe Francophone de Cancerologie Thoracique
Northwestern University
Incyte Corporation
Henan Cancer Hospital
Case Comprehensive Cancer Center
Hoosier Cancer Research Network
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Barbara Ann Karmanos Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Turin, Italy
CTI BioPharma
Guangzhou Institute of Respiratory Disease